Skip to content
buyNotable cluster of 4

Markus Puhlmann bought $189k of CATX

Chief Medical Officer at Perspective Therapeutics, Inc.. 595,425 shares at an average of $0.32, traded Dec 15, 2023, filed Dec 19, 2023.

Conviction score
60
Value
$189k
595,425 shares
Holdings after
1,095,425
+119% from before
From 52-week low
+29%
low $2.10, close $2.70
From 52-week high
-63%
high $7.20, as of Dec 15, 2023

Score components

  • Role
    Officer
    +15
  • Trade size
    $189k at market
    +12
  • Relative to holdings
    Holdings up 119%
    +10
  • Price context
    62% below the 52-week high
    +8
  • Cluster
    4 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CATXOct 12, 2026 · close 2.52
Since filing Dec 19, 2023: -25.9%SPY +69.2% · excess -95.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001437749-23-034931, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 15, 2023POpen-market purchase
Common Stock
+135,006$0.27$36k635,006Dec 19, 2023
Dec 18, 2023POpen-market purchase
Common Stock
+60,419$0.26$15k695,425Dec 19, 2023
Dec 19, 2023POpen-market purchase
Common Stock
+400,000$0.34$137k1,095,425Dec 19, 2023

Related signals

Other insiders at Perspective Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
42Moderate
CATXsell 2
Perspective Therapeutics, Inc.
Lantheus Alpha Therapy, LLC
owner
$777k
247,932 shares
-2%
35Weak
CATXsell 2
Perspective Therapeutics, Inc.
Lantheus Alpha Therapy, LLC
owner
$357k
113,914 shares
-1%
31Weak
CATXsell 2
Perspective Therapeutics, Inc.
Lantheus Alpha Therapy, LLC
owner
$131k
42,129 shares
-0%
30Weak
CATXsell 2
Perspective Therapeutics, Inc.
Lantheus Holdings, Inc.
owner
$112k
35,769 shares
-0%
33Weak
CATXsell 2
Perspective Therapeutics, Inc.
Lantheus Holdings, Inc.
owner
$246k
78,145 shares
-1%
37Weak
CATXbuy 2
Perspective Therapeutics, Inc.
Jonathan Robert Hunt
Chief Accounting Officer
$22k
11,000 shares
+23%
41Moderate
CATXbuy 2
Perspective Therapeutics, Inc.
Robert F Williamson III
director
$20k
9,498 shares
+2595%
73Notable
CATXbuy 4
Perspective Therapeutics, Inc.
Juan Graham
Chief Financial Officer
$75k
33,333 shares
+1649%
58Moderate
CATXbuy 4
Perspective Therapeutics, Inc.
Lori A Woods
director
$50k
23,475 shares
+15%
69Notable
CATXbuy 4
Perspective Therapeutics, Inc.
Robert F Williamson III
director
$132k
60,337 shares
+124%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Markus Puhlmann bought $189k of CATX | InsiderTell